Literature DB >> 33473122

Short H2A histone variants are expressed in cancer.

Guo-Liang Chew1, Marie Bleakley2, Robert K Bradley3,4,5, Harmit S Malik4,6, Steven Henikoff4,6, Antoine Molaro7,8, Jay Sarthy9.   

Abstract

Short H2A (sH2A) histone variants are primarily expressed in the testes of placental mammals. Their incorporation into chromatin is associated with nucleosome destabilization and modulation of alternate splicing. Here, we show that sH2As innately possess features similar to recurrent oncohistone mutations associated with nucleosome instability. Through analyses of existing cancer genomics datasets, we find aberrant sH2A upregulation in a broad array of cancers, which manifest splicing patterns consistent with global nucleosome destabilization. We posit that short H2As are a class of "ready-made" oncohistones, whose inappropriate expression contributes to chromatin dysfunction in cancer.

Entities:  

Year:  2021        PMID: 33473122      PMCID: PMC7817690          DOI: 10.1038/s41467-020-20707-x

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  55 in total

Review 1.  Histone variants: essential actors in male genome programming.

Authors:  Naghmeh Hoghoughi; Sophie Barral; Alexandra Vargas; Sophie Rousseaux; Saadi Khochbin
Journal:  J Biochem       Date:  2018-02-01       Impact factor: 3.387

2.  The biology of cancer testis antigens: putative function, regulation and therapeutic potential.

Authors:  Elisabetta Fratta; Sandra Coral; Alessia Covre; Giulia Parisi; Francesca Colizzi; Riccardo Danielli; Hugues Jean Marie Nicolay; Luca Sigalotti; Michele Maio
Journal:  Mol Oncol       Date:  2011-02-18       Impact factor: 6.603

3.  A Mutation in Histone H2B Represents a New Class of Oncogenic Driver.

Authors:  Richard L Bennett; Aditya Bele; Eliza C Small; Christine M Will; Behnam Nabet; Jon A Oyer; Xiaoxiao Huang; Rajarshi P Ghosh; Adrian T Grzybowski; Tao Yu; Qiao Zhang; Alberto Riva; Tanmay P Lele; George C Schatz; Neil L Kelleher; Alexander J Ruthenburg; Jan Liphardt; Jonathan D Licht
Journal:  Cancer Discov       Date:  2019-07-23       Impact factor: 39.397

4.  Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Authors:  Fiona M Behan; Francesco Iorio; Gabriele Picco; Kosuke Yusa; Mathew J Garnett; Emanuel Gonçalves; Charlotte M Beaver; Giorgia Migliardi; Rita Santos; Yanhua Rao; Francesco Sassi; Marika Pinnelli; Rizwan Ansari; Sarah Harper; David Adam Jackson; Rebecca McRae; Rachel Pooley; Piers Wilkinson; Dieudonne van der Meer; David Dow; Carolyn Buser-Doepner; Andrea Bertotti; Livio Trusolino; Euan A Stronach; Julio Saez-Rodriguez
Journal:  Nature       Date:  2019-04-10       Impact factor: 49.962

5.  A new link between transcriptional initiation and pre-mRNA splicing: The RNA binding histone variant H2A.B.

Authors:  Tatiana A Soboleva; Brian J Parker; Maxim Nekrasov; Gene Hart-Smith; Ying Jin Tay; Wei-Quan Tng; Marc Wilkins; Daniel Ryan; David J Tremethick
Journal:  PLoS Genet       Date:  2017-02-24       Impact factor: 5.917

6.  Differential contribution of p300 and CBP to regulatory element acetylation in mESCs.

Authors:  Sara Martire; Jennifer Nguyen; Aishwarya Sundaresan; Laura A Banaszynski
Journal:  BMC Mol Cell Biol       Date:  2020-07-20

7.  Regulation of alternative splicing by p300-mediated acetylation of splicing factors.

Authors:  Ahmad Siam; Mai Baker; Leah Amit; Gal Regev; Alona Rabner; Rauf Ahmad Najar; Mercedes Bentata; Sara Dahan; Klil Cohen; Sarah Araten; Yuval Nevo; Gillian Kay; Yael Mandel-Gutfreund; Maayan Salton
Journal:  RNA       Date:  2019-04-15       Impact factor: 4.942

8.  TopHat: discovering splice junctions with RNA-Seq.

Authors:  Cole Trapnell; Lior Pachter; Steven L Salzberg
Journal:  Bioinformatics       Date:  2009-03-16       Impact factor: 6.937

9.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11.

Authors:  Claus Lundegaard; Kasper Lamberth; Mikkel Harndahl; Søren Buus; Ole Lund; Morten Nielsen
Journal:  Nucleic Acids Res       Date:  2008-05-07       Impact factor: 16.971

10.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data.

Authors:  Antonio Colaprico; Tiago C Silva; Catharina Olsen; Luciano Garofano; Claudia Cava; Davide Garolini; Thais S Sabedot; Tathiane M Malta; Stefano M Pagnotta; Isabella Castiglioni; Michele Ceccarelli; Gianluca Bontempi; Houtan Noushmehr
Journal:  Nucleic Acids Res       Date:  2015-12-23       Impact factor: 16.971

View more
  8 in total

Review 1.  Histone variants: The unsung guardians of the genome.

Authors:  Ernest O N Phillips; Akash Gunjan
Journal:  DNA Repair (Amst)       Date:  2022-02-17

2.  Analysis of histone variant constraint and tissue expression suggests five potential novel human disease genes: H2AFY2, H2AFZ, H2AFY, H2AFV, H1F0.

Authors:  Emily Lubin; Laura Bryant; Joseph Aicher; Dong Li; Elizabeth Bhoj
Journal:  Hum Genet       Date:  2022-01-24       Impact factor: 5.881

Review 3.  Large-Scale Chromatin Rearrangements in Cancer.

Authors:  Kosuke Yamaguchi; Xiaoying Chen; Asami Oji; Ichiro Hiratani; Pierre-Antoine Defossez
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

Review 4.  Histone H1 Mutations in Lymphoma: A Link(er) between Chromatin Organization, Developmental Reprogramming, and Cancer.

Authors:  Alexey A Soshnev; C David Allis; Ethel Cesarman; Ari M Melnick
Journal:  Cancer Res       Date:  2021-09-27       Impact factor: 13.312

5.  Effects of Oncohistone Mutations and PTM Crosstalk on the N-Terminal Acetylation Activities of NatD.

Authors:  Yi-Hsun Ho; Rong Huang
Journal:  ACS Chem Biol       Date:  2022-01-19       Impact factor: 4.634

6.  Novel Classes and Evolutionary Turnover of Histone H2B Variants in the Mammalian Germline.

Authors:  Pravrutha Raman; Mary C Rominger; Janet M Young; Antoine Molaro; Toshio Tsukiyama; Harmit S Malik
Journal:  Mol Biol Evol       Date:  2022-02-03       Impact factor: 16.240

Review 7.  Alternative Splicing, Epigenetic Modifications and Cancer: A Dangerous Triangle, or a Hopeful One?

Authors:  Francisco Gimeno-Valiente; Gerardo López-Rodas; Josefa Castillo; Luis Franco
Journal:  Cancers (Basel)       Date:  2022-01-22       Impact factor: 6.639

8.  H2A.B is a cancer/testis factor involved in the activation of ribosome biogenesis in Hodgkin lymphoma.

Authors:  Xuanzhao Jiang; Jiayu Wen; Elizabeth Paver; Yu-Huan Wu; Gege Sun; Amanda Bullman; Jane E Dahlstrom; David J Tremethick; Tatiana A Soboleva
Journal:  EMBO Rep       Date:  2021-07-19       Impact factor: 9.071

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.